Role of mineralocorticoid receptor antagonism in diuretic therapy of congestive heart failure;Stellenwert der aldosteronrezeptorblockade in der diuretischen therapie von patienten mit chronischer herzinsuffizienz

Herz

Volumn 27, Issue 2, 2002, Pages 135-149

  Christ, Michael ^a   Ludwig, Nils ^a   Maisch, Bernhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Aldosterone; Congestive heart failure; Diuresis; Hypokalemia; Spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; POTASSIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ARTICLE; CONGESTIVE HEART FAILURE; DIURESIS; DIURETIC THERAPY; HUMAN; HYPOKALEMIA; KIDNEY FUNCTION; SODIUM ABSORPTION; SODIUM RESTRICTION; WATER DEPRIVATION;

BENZOTHIADIAZINES; DIURETICS; DIURETICS, OSMOTIC; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; RECEPTORS, ALDOSTERONE; SODIUM CHLORIDE SYMPORTER INHIBITORS; WATER-ELECTROLYTE BALANCE;

EID: 0036223274     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-002-2352-0     Document Type: Article

References (112)

1. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results
2. Ventricular extrasystoles during thiazide treatment: Substudy of MRC mild hypertension trial
3. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial
4. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
5. Comparative effects of therapy with captopril and digoxin in patients with mild to mode-rate heart failure
6. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])
7. The urinary sodium: Potassium ratio and response to diuretics in resistant oedema
8. A double-blind, cross-over comparison of the effects of a loop diuretic and a dopamine receptor agonist as first line therapy in patients with mild congestive heart failure
9. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: Mechanistic evidence to support RALES
10. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction. Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression
11. Untreated heart failure: Clinical and neuroendocrine effects of introducing diuretics
12. Role of aldosterone in the control of sodium excre-tion in patients with advanced chronic renal failure
13. Mannitol intoxication in patients with renal failure
14. The role of the kidney in the early nondiuretic action of furosemide to reduce elevated left atrial pressure in the hypervolemic dog
15. Diuretic therapy
16. Furosemide in patients with heart failure: Shift in dose-response curves
17. The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure
18. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis
19. Renal tubular chloride transport and the mode of action of some diuretics
20. Relation between potassium balance and aldosterone secretion in normal subjects and in patients with hypertensive or renal tubular disease
21. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure
22. Angiotensin II: A powerful controller of sodium transport in the early proximal tubule
23. The management of chronic heart failure
24. Randomised trial of highdose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema
25. Symptomatic assessment of patients with heart failure: Double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure
26. Relation of arrhythmias and electrolyte abnormalities to survival in patients with severe chronic heart failure
27. Cardiac aldosterone production and ventricular remodeling
28. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction
29. Fate of potassium supplements in six outpatients receiving long-term diuretics for oedematous disease
30. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure
31. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction
32. Second line therapy of congestive heart failure with torase-mide
33. Relation of cardiovascular disease to potassium and magnesium deficiencies
34. Plasma and skeletal muscle electrolytes in patients on long-term diuretic therapy for arterial hypertension and/or congestive heart failure
35. Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension
36. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure
37. Attenuated renal excretory response to atrial natriuretic peptide in congestive heart failure in man
38. Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infu-sion
39. Role of duration of diuretic effect in preventing sodium retention
40. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappa b activation in angiotensin II-induced cardiac injury
41. Influence of ADH on renal potassium handling: A micropuncture and microperfusion study
42. Resistanceto remnant nephropathy in the Wistar-Furth rat
43. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure
44. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis
45. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program
46. Diuretic complications
47. Role of aldosterone in the remnant kidney model in the rat
48. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy
49. Plasma aldosterone concentrations in chronic renal disease
50. Renal function, neurohormonal activation, and survival in patients with chronic heart failure
51. Survival after the onset of congestive heart failure in Framingham Heart Study subjects
52. Diuretic-induced ventricular ectopic activity
53. Aldosterone in renal disease
54. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure)
55. A study of two diuretic/potassium combinations in heart failure
56. Role of the renin-angiotensin-aldoste-rone system in the progression of renal disease: A critical review
57. Factors modifying the early nondiuretic vascu-lar effects of furosemide in man. The possible role of renal prostaglandins
58. Efficacy of low-dose captopril in addition to furose-mide and spironolactone in patients with decompensated liver disease during blunted diuresis
59. Aldosterone and prolactin responsiveness after prolonged treatment of congestive heart failure with captopril
60. Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure
61. Effects of flow rate and potassium intake on distal tubular potassium transfer
62. Sequential nephron blockade breaks resistance to diuretics in edematous states
63. Diuretic therapy and diuretic resistance in cardiac failure
64. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure
65. Physiologic and clinical observations on furosemide and ethacrynic acid
66. The effect of chlorothiazide on electrolyte transport in man: Its use in the treatment of edema of congestive heart failure, nephrosis and cirrhosis
67. K+ depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion
68. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy
69. Hypokalaemia and diuretics: An analysis of publications
70. Experimentally induced chronic renal insufficiency in the rat
71. Diuretic therapy and ventricular arrhythmias in persons 65 years of age and older
72. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion
73. Combined therapy with thiazidetype and loop diuretic agents for resistant sodium retention
74. Effectiveness of potassium chloride or triamterene in thiazide hypokalemia
75. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
76. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy
77. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
78. ACE inhibitor co-therapy in patients with heart failure: Rationale for the Randomized Aldactone Evaluation Study (RALES)
79. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level
80. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction
81. Guidelines for the diagnosis and treatment of chronic heart failure
82. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure
83. Antidiuretic hormone in congestive heart failure
84. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats
85. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats
86. Pathophysiological effects of aldosterone in cardiovascular tissues
87. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy
88. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
89. Prevalence and mortality rate of congestive heart failure in the United States
90. Hormones and hemodynamics in heart failure
91. Pathogenesis of sodium and water retention in cardiac failure
92. Haemodynamic impact of diuretic therapy in chronic heart failure
93. Diuretic therapy for hypertension and the risk of primary cardiac arrest
94. Spironolactone in the long-term management of patients with congestive heart failure
95. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
96. Effects of pH on potassium transport by renal distal tubule
97. Controlled double-blind clinical trial of the efficacy and tolerance of torasemide in comparison with furosemide in patients with congestive heart failure
98. Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease
99. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart fai-lure (the Randomized Aldactone Evaluation Study [RALES])
100. Distribution of mineralocorticoid and glucocorticoid receptor mRNA along the nephron
101. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor
102. Bioavailability, pharmaco-kinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure
103. Furosemide absorption altered in decompensated congestive heart failure
104. Control by drugs of renal potassium handling
105. Relation of plasma renin to end organ damage and to protection of K+ feeding in strokeprone hypertensive rats
106. Hypertension-related renal injury: A major contributorto end-stage renal disease
107. Mannitol
108. Aldosterone and spironolactone in heart failure
109. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation
110. Effects of low-dose aspirin on responses to furosemide
111. Potassium's cardiovascular protective mechanisms
112. The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis